OraSure Technologies (NASDAQ:OSUR) Downgraded by StockNews.com to "Hold"

OraSure Technologies (NASDAQ:OSUR - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Saturday.

OraSure Technologies Stock Performance

OraSure Technologies stock opened at $3.80 on Friday. OraSure Technologies has a fifty-two week low of $3.52 and a fifty-two week high of $8.04. The firm has a 50 day moving average price of $3.81 and a 200 day moving average price of $4.03. The company has a market capitalization of $283.44 million, a PE ratio of 25.33 and a beta of 0.05.

Institutional Trading of OraSure Technologies

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its holdings in OraSure Technologies by 27.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier's stock valued at $3,655,000 after purchasing an additional 183,191 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of OraSure Technologies by 28.5% in the third quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier's stock worth $1,091,000 after acquiring an additional 59,723 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of OraSure Technologies by 5.8% in the third quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier's stock worth $3,621,000 after acquiring an additional 46,216 shares in the last quarter. Barclays PLC grew its stake in shares of OraSure Technologies by 182.6% in the third quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier's stock worth $836,000 after acquiring an additional 126,503 shares in the last quarter. Finally, Exchange Traded Concepts LLC acquired a new position in shares of OraSure Technologies in the fourth quarter worth $287,000. Institutional investors and hedge funds own 93.50% of the company's stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.